Kenshi Suzuki

12PUBLICATIONS
48CO-AUTHORS
NanomedicineCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCellular immunologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jun 03, 2026
Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS.

|May 12, 2026
Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis.

|Mar 27, 2026
Daratumumab plus VRd in Japanese transplant-ineligible/deferred NDMM patients: Japanese subgroup of the CEPHEUS trial.

Kenshi Suzuki, Morio Matsumoto, Hiroyuki Takamatsu

|Jul 17, 2025
Can baseline cytomegalovirus IgG titers predict cytomegalovirus reactivation after ide-cel therapy?

Taku Kikuchi, Ukyo Kondo, Shotaro Sugita

|Dec 04, 2023
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX.

Andrew Spencer, Philippe Moreau, Maria-Victoria Mateos

|Nov 29, 2023
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial.

Paul G Richardson, Thierry Facon, Christopher P Venner

Pageof 2

Frequent Collaborators

2 joint publications

Vania Hungria

2 joint publications

Sung-Soo Yoon

2 joint publications

Meral Beksac

2 joint publications

Efstathios Kastritis